Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 3

IDERA PHARMACEUTICALS, INC. Form 3 November 14, 2011 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

Statement

(Month/Day/Year) 11/04/2011

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

4. Relationship of Reporting

IDERA PHARMACEUTICALS, INC. [IDRA]

(Print or Type Responses)

Person *

(Last)

1. Name and Address of Reporting

Pillar Pharmaceuticals I LP

(First)

(Middle)

			Person(s) to	Filed(Month/Day/Year)				
PILLAR INVEST OFFSHORE SAL STARCO CTR, BLOC B, 3RD FLR, OMAR DAOUK ST (Street) BEIRUT, M8 2020-3313		BLOC B, DUK ST	(Chec X Direct Officer (give title belo	wner 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table I - Non-Deriva	ivative Securities Beneficially Owned				
1.Title of Secur (Instr. 4)	ity		2. Amount of Securities Beneficially Owned (Instr. 4)	Ownership C	. Nature of Indirect Beneficial Ownership Instr. 5)			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a				SEC 1473 (7-02)				
T	curren	tly valid OMB control n		s, warrants, optio	ns, convertible securities)			

1. Title of Derivative Security (Instr. 4)	, ,		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
			(Instr. 4)	/		Derivative	(Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

OMB APPROVAL

5. If Amendment, Date Original

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Warrants	11/04/2011	11/04/2016	Common Stock	2,810,650	\$ 1.6275	Ι	See Footnote (1)
Series D Convertible Preferred Stock	(2)	(2)	Common Stock	<u>(2)</u>	\$ <u>(2)</u>	Ι	See Footnote (1)

Reporting Owners

Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
Pillar Pharmaceuticals I LP PILLAR INVEST OFFSHORE SAL STARCO CTR BLOC B, 3RD FLR, OMAR DAOUK ST BEIRUT, M8 2020-3313	ÂX	ÂX	Â	Â	
Pillar Invest Corp PILLAR INVEST OFFSHORE SAL STARCO CTR BLOC B, 3RD FLR, OMAR DAOUK ST BEIRUT, M8 2020-3313	ÂX	X	Â	Â	
Signatures					
Pillar Pharmaceuticals I LP, /s/ Youssef El Zein, Autho Signatory	11/14/2011				
**Signature of Reporting Person	Date				
Pillar Invest Corporation, /s/ Youssef El Zein, Authorit Signatory	11/14/2011				
<u>**</u> Signature of Reporting Person			Dat	te	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Pillar Pharmaceuticals I LP ("Pillar") directly owns the shares of Series D Convertible Preferred Stock and the warrants (together, the
"Securities"). Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar. Pillar GP disclaims beneficial ownership of the Securities, except to the extent of its pecuniary interest, if any, in the Securities by virtue of its general partner interest in Pillar.

(2) The Series D Convertible Preferred Stock is convertible at any time, at the holder's election, on a 1-for-5 basis (subject to adjustment and certain other limitations on conversion), into shares of Common Stock and does not have an expiration date.

Â

Remarks:

Youssef El Zein is a director and controlling stockholder of Pillar GP and serves as the representa of directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.